ONL Therapeutics (ONL) is a clinical stage biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal diseases and conditions.
By advancing a novel breakthrough technology designed to protect photoreceptors against apoptotic and inflammatory cell death, ONL is pioneering an entirely new approach to preserving sight. It is the first and only company focused on preventing the death of retinal cells - the root cause of vision loss and the leading cause of blindness.
Based on its industry-leading expertise in photoreceptor protection, ONL is developing breakthrough treatments for serious, vision-threatening retinal diseases and conditions. Lead therapeutic candidate, ONL1204, is a first-in-class small molecule peptide initially being for the protection of photoreceptors in retinal detachment. Preclinical data to date for ONL1204 demonstrates the drug's ability to protect photoreceptors against the apoptosis process triggered by retinal detachment.
By advancing a novel breakthrough technology designed to protect photoreceptors against apoptotic and inflammatory cell death, ONL is pioneering an entirely new approach to preserving sight. It is the first and only company focused on preventing the death of retinal cells - the root cause of vision loss and the leading cause of blindness.
Based on its industry-leading expertise in photoreceptor protection, ONL is developing breakthrough treatments for serious, vision-threatening retinal diseases and conditions. Lead therapeutic candidate, ONL1204, is a first-in-class small molecule peptide initially being for the protection of photoreceptors in retinal detachment. Preclinical data to date for ONL1204 demonstrates the drug's ability to protect photoreceptors against the apoptosis process triggered by retinal detachment.
Location: United States, Michigan, Ann Arbor
Employees: 11-50
Total raised: $158.8M
Founded date: 2011
Investors 4
| Date | Name | Website |
| 06.12.2024 | Accelerate... | accelerate... |
| 17.03.2023 | Visionary ... | visionaryv... |
| - | Invest Mic... | investmich... |
| - | Grand Ange... | michiganca... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 16.09.2024 | Series D | $65M | - |
| 13.01.2022 | Series B | $46.9M | - |
| 24.12.2020 | Series B | $46.9M | - |
Mentions in press and media 18
| Date | Title | Description |
| 16.09.2024 | ONL Therapeutics Closes $65M Series D Financing | ONL Therapeutics, an Ann Arbor, MI-based clinical-stage biopharmaceutical company focused on advancing treatments of geographic atrophy (GA) associated with dry age-related macular degeneration (AMD), raised $65M in Series D funding. The ro... |
| 13.09.2024 | ONL Therapeutics Secures $65 Million to Revolutionize Vision Care | In the heart of Ann Arbor, a beacon of hope for vision preservation shines brighter. ONL Therapeutics, a clinical-stage biopharmaceutical company, has successfully closed a $65 million Series D financing round. This funding is not just a nu... |
| 13.09.2024 | ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing | Funds will advance the development of ONL1204 Ophthalmic Solution with the initiation of a Phase 2 global study for the treatment of geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) ANN ARBOR, Mich., Sept. ... |
| 13.09.2024 | ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing | ANN ARBOR, Mich., Sept. 13, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that it has secur... |
| 08.03.2023 | ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial | - |
| 13.01.2022 | ONL Therapeutics Closes 2nd Tranche of $46.9M Series B Financing | ONL Therapeutics, Inc.,, an Ann Arbor, Mich.-based clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, closed on its second tranche of its Series B financing. The t... |
| 13.01.2022 | Eye disease biotech raises $46.9M in Series B; Journey Medical Corporation shells out $20M upfront for dermatology franchise | ONL Therapeutics — an Ann Arbor, MI biotech that got its initial backing from Novartis in a 2017 Series A for its lead candidate Fas inhibitor ONL1204 — just got its next cash infusion. The biotech announced this morning tha... |
| 13.01.2022 | ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones | – Lead candidate ONL1204 Ophthalmic Solution has advanced into chronic indications of open-angle glaucoma (OAG) and geographic atrophy (GA) associated with age-related macular degeneration (AMD) – – Phase 1b studies in patients with OAG and... |
| 13.01.2022 | ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones | – Lead candidate ONL1204 Ophthalmic Solution has advanced into chronic indications of open-angle glaucoma (OAG) and geographic atrophy (GA) associated with age-related macular degeneration (AMD) – – Phase 1b studies in patients with OAG and... |
| 26.12.2020 | ONL Therapeutics secures US$ 46.9M in Series B funding | - |
Show more